Development of probiotics as biologic drugs

Area of Science:

• Microbiology
• Pharmacology
• Regulatory Science

Background:

• Probiotics are live microorganisms intended to confer a health benefit.
• In the United States, the regulatory status of probiotics depends on their intended use and claims.
• Products affecting body structure or function for disease prevention/treatment are classified as drugs.

Purpose of the Study:

• To provide a historical overview of US drug and biologic regulation.
• To explore the legal, regulatory, and policy considerations for probiotics.
• To examine probiotics specifically as biologic drugs for human use.

Main Methods:

• Literature review of historical drug and biologic regulations in the US.
• Analysis of current legal and policy frameworks governing probiotics.
• Examination of regulatory pathways for probiotics classified as biologic drugs.

Main Results:

• The US regulates probiotics as drugs if they are intended to treat, cure, mitigate, or prevent disease.
• Historical context reveals evolving regulatory approaches to medical products.
• Probiotics intended for therapeutic use face stringent regulatory scrutiny.

Conclusions:

• Probiotics intended for therapeutic purposes in the US are subject to drug regulations.
• Understanding the regulatory landscape is crucial for developing and marketing probiotic products.
• Classification as a biologic drug necessitates adherence to specific legal and policy requirements.